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Induction of Epidermolysis Bullosa Acquisita in Mice
by Passive Transfer of Autoantibodies from Patients
David T. Woodley1, Ramin Ram1, Arvin Doostan1, Pubali Bandyopadhyay1, Yi Huang1, Jennifer Remington1,
Yingping Hou1, Douglas R. Keene2, Zhi Liu3 and Mei Chen1
Epidermolysis bullosa acquisita (EBA) is an autoimmune sub-epidermal blistering disease characterized by
autoantibodies to type VII (anchoring fibril) collagen. To date, however, direct evidence for a pathogenic role of
human EBA autoantibodies has not been demonstrated. In this study, we affinity-purified anti-type VII collagen
antibodies from EBA patients’ sera and then injected them into adult hairless immunocompetent mice. Mice
injected with EBA autoantibodies developed skin fragility, blisters, erosions, and nail loss on their paws – all
features of EBA patients. By clinical, histological, immunological, and ultrastructural parameters, the induced
lesions were reminiscent of human EBA. Histology showed bullous lesions with an epidermal–dermal
separation. IgG and C3 deposits were observed at the epidermal–dermal junction. All mice had serum
antibodies that labeled the dermal side of salt-split human skin like EBA sera. Direct immunogold electron
microscopy specifically localized deposits of human IgG to anchoring fibrils. (Fab0)2 fragments generated from
EBA autoantibodies did not induce disease. We conclude that EBA human patient autoantibodies cause sub-
epidermal blisters and induce EBA skin lesions in mice. These passive transfer studies demonstrate that human
EBA autoantibodies are pathogenic. This novel EBA mouse model can be used to further investigate EBA
autoimmunity and to develop possible therapies.
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INTRODUCTION
Epidermolysis bullosa acquisita (EBA) is an acquired auto-
immune blistering disease of the skin (Roenigk et al., 1971).
EBA patients have autoantibodies in their blood and skin
directed against structures in the skin called anchoring fibrils
(Woodley et al., 1984, 1986, 1988). Anchoring fibrils are
located at the dermal–epidermal junction (DEJ) of skin and
function to adhere the epidermal layer of the skin onto the
dermal layer (Briggaman and Wheeler, 1975; Sakai et al.,
1986; Burgeson, 1993). Although the precise role of
autoantibodies to type VII collagen in the pathogenesis of
EBA remains to be established, it is very likely that anchoring
fibrils are critical for the epidermal layer of skin to adhere to
the dermal layer. Evidence for this is that patients who are
born with a defect in the gene that encodes for type VII
collagen have a paucity of normal anchoring fibrils and
exhibit skin fragility and skin blisters just like EBA patients
(Uitto and Christiano, 1992, 1994).
Anchoring fibrils, wheat-stack-shaped structures in the
skin that hold the epidermis and dermis together, are
composed of type VII collagen (Sakai et al., 1986; Keene
et al., 1987). This collagen is composed of three identical
alpha chains, each consisting of a 145 kDa central collagen-
ous triple-helical segment characterized by repeating Gly-X-Y
amino-acid sequences, flanked by a large 145 kDa amino-
terminal, non-collagenous domain (NC1), and a smaller
34 kDa carboxy-terminal non-collagenous domain (NC2)
(Burgeson, 1993). We and others have shown that the NC1
domain of type VII collagen is highly antigenic and that most
EBA autoantibodies are directed against sub-domains within
NC1 (Gammon et al., 1993; Lapiere et al., 1993; Jones et al.,
1995).
The etiology of EBA is unknown. Nevertheless, there is
some evidence to suggest that antibodies to type VII collagen
may be pathogenic and able to cause epidermal–dermal
disadherence. Recently, we immunized rabbits and raised a
high titer antiserum to the NC1 domain of human type VII
collagen. We injected this antibody into hairless immuno-
competent mice and the mice developed a skin condition
that had many of the features of EBA in humans (Woodley
et al., 2005). Another recent study by Sitaru et al. (2005)
showed that the injection of rabbit polyclonal antibodies to
the NC1 domain of mouse type VII collagen into adult nude,
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BALB/c, and C57BL/6 mice also induced sub-epidermal skin
blisters that were reminiscent of human EBA.
Although these studies with antibodies raised in rabbits
against human or mouse type VII collagen are suggestive and
interesting, they do not truly meet the autoimmune disease
equivalent of ‘‘Koch’s Postulate’’, which is to demonstrate
that the human patient’s autoantibody can duplicate the
disease in an animal (Witebsky, 1966; Rose and Bona, 1993).
In this regard, all previous attempts to develop an animal
model using EBA patients’ autoantibodies transferred pas-
sively into animals were unsuccessful (Shigemoto et al.,
1988; Chen et al., 1992; Borradori et al., 1995).
In this report, we affinity purified anti-NC1 autoantibodies
from EBA patients’ sera and injected the antibodies into adult
immunocompetent, hairless mice. We found that the animals
developed a sub-epidermal bullous disease with clinical, histo-
logical, immunological, and ultrastructural features similar
to human EBA. These results provide evidence that human
EBA autoantibodies to the NC1 domain of type VII collagen
are pathogenic and capable of inducing epidermal–dermal
separation of skin.
RESULTS
Characteristics of affinity-purified EBA IgG fractions
We affinity-purified antibodies to the NC1 domain of type VII
collagen from the sera of two EBA patients who were
plasmaphoresed for therapeutic purposes. The antigenic
specificity of the anti-type VII collagen antibodies was
characterized by immunoblot analysis as shown in
Figure 1a. The antibodies only labeled the 145 kDa NC1
domain of type VII collagen (lane 1) and did not label other
matrix proteins including type I collagen, type IV collagen,
fibronectin, laminin-1, and laminin-5 (Figure 1a, lanes 2–6).
To determine whether the purified antibodies reacted with
murine skin, we performed indirect immunofluorescence (IIF)
analysis on both human and murine skin. As shown in Figure
1b, the antibodies strongly labeled the basement membrane
zone (BMZ) of both human and mouse skin at dilution titers
over 1:50,000. The control IgG fraction purified from normal
human sera did not label either mouse or human skin (data
not shown). IIF testing against salt-split human skin substrate
revealed that the antibody bound to the dermal side of the
salt-split skin, consistent with labeling-type VII (anchoring
fibril) collagen and characteristic of EBA serum (Gammon
et al., 1984, 1990).
Clinical evaluation of mice injected with EBA antibodies
SKH1 mice were given daily intradermal injections of
affinity-purified anti-type VII collagen antibodies from EBA
sera or control normal human sera at doses from 20 to
100mg/g body weight/per day. The characteristics of the EBA
anti-type VII collagen antibodies are outlined in Table 1. As
shown in Figure 2, animals injected with the EBA anti-type
VII collagen antibodies (n¼40) showed numerous blisters,
erosions, and crusts forming from ruptured blisters as early as
day four in the middle back near the injection sites (Figure
2a). With time, additional lesions were observed on the body
(Figure 2b and c), ears, and paws of the animals (Figure 2d)
with subsequent injections. Nail loss was observed in 70% of
the injected mice (Figure 2e and f). Mice continued to
develop new widespread lesions even 6 weeks after the initial
series of injections (Figure 2c). As summarized in Table 1,
cutaneous lesions occurred in 36 of 40 experimental mice
given EBA antibodies. In contrast, none of the 10 animals that
received identical doses of control IgG injections developed
any cutaneous lesions. Furthermore, five animals injected
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Figure 1. Characterization of affinity-purified EBA antibodies. (a) The figure
shows the specificity of affinity-purified EBA autoantibodies for the NC1
domain of type VII collagen. Purified recombinant NC1 as well as other
extracellular matrix components (400 ng/well) were separated on a 6%
SDS-PAGE gel and transferred to nitrocellulose membranes. The transferred
proteins were incubated with affinity-purified EBA antibodies at a dilution of
1:2,000 and horseradish peroxidase conjugated anti-human IgG (1:5,000)
followed by ECL detection. Lanes 1, 2, 3, 4, 5, and 6 are NC1, type I collagen,
type IV collagen, fibronectin, laminin-1, and laminin-5, respectively. The
location of the 145 kDa recombinant NC1 and molecular weight markers are
indicated. (b–d) The figure shows immunolabeling of mouse and human skin
with the affinity-purified EBA antibodies. Immunofluorescence staining was
performed on (b) human skin, (c) mouse skin, and (d) salt-split human skin.
The tissue was labeled with EBA antibodies diluted 1:1,000 and an FITC-
conjugated goat anti human IgG. Note that the affinity-purified EBA antibody
strongly labeled the BMZ of both mouse and human skin and the dermal floor
of salt-split human skin. d, dermis; e, epidermis. Bars, 200 mM.
Table 1. Characterization of the affinity-purified EBA
antibodies used and the incidence of disease in
injected mice
Source of IgG IIF titer1
Dose of IgG
injected lg/g of
body weight/day
No. of mice
with skin
lesions2
Patient 1 50,000 20–100 19/20
Patient 2 50,000 20–100 17/20
Control IgG3 0 20–400 0/10
Flow-through IgG4 0 20–400 0/5
1Titers of concentrated affinity-purified EBA antibodies tested against
normal mouse skin.
2The numerator denotes the number of mice in which skin lesions
developed; the denominator denotes the total number of mice that
received injections.
3From pooled normal human serum.
4Flow-through IgG were from flow-through fractions of NC1 affinity
column that were depleted the reactivity to the NC1 domain.
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with EBA IgG depleted of reactivity to the NC1 domain of
type VII collagen (flow-through fractions from NC1 affinity
column) did not develop blisters.
Given the nature of our experimental protocol, it is
impossible to know the exact kinetics of a single injection
inducing a given lesion. This is because we injected animals
every single day for 8 days. If we observed a blister or multiple
blisters arising on day 4, for example, we can not tell if that
blister arose because of the injection at any particular day.
We examined the correlation between the extent of clinical
skin lesions and the dose of IgG injected by studying 12
additional animals. As shown in Figure 2g–i, mice injected
with high doses of EBA antibodies (450mg/g body weight/per
day (n¼4)) developed more lesions (þ þ ) than animals
injected with lower doses of EBA antibodies (10mg/g body
weight/per day (n¼4)) (þ ). Animals injected with only 2.5mg/
g body weight (n¼4) of EBA antibodies exhibited no lesions at
all (). Table 2 summarizes the results of these dose–response
studies. These data demonstrate that increasing the amount of
injected IgG results in an increase in the circulating titer of
BMZ specific anti-type VII collagen antibody, which, in turn,
was associated with increased skin lesions.
Histological and immunological examination of mice injected
with EBA antibodies
Histological examination of lesional skin from mice injected
with EBA antibodies showed a full sub-epidermal blister with a
clean separation between the epidermis and dermis (Figure 3a).
There was also a mild to moderate scattered dermal
inflammatory infiltrate consisting mostly of mononuclear cells
and a few neutrophils. In contrast, mice injected with similar
concentrations of control normal human IgG demonstrated a
normal epidermis and dermis without any pathological
alterations (Figure 3b).
Direct immunofluorescence (DIF) of perilesional and
lesional skin demonstrated that all of the mice injected
with EBA antibodies had human IgG deposits at the DEJ
(Figure 3c). Also, in 85% (34 out of 40) of the injected mice,
murine complement component C3 deposits were detected
at the DEJ (Figure 3c). Within the dermal inflammatory
infiltrate, neutrophils could be detected (Figure 3c). In
contrast, no IgG, C3, or neutrophils were observed in the
skin of mice receiving equivalent amounts of control normal
human IgG.
Mice that received injections of EBA antibodies had titers
of circulating antibody (1:500–1:2,000) when assayed by IIF
against either normal or salt-split human skin. This titer is
comparable to the starting antibody titer of crude EBA sera
before purification (1:1,280–1:5,120). As shown in Figure 4,
serum samples from the experimental mice had human
antibodies that labeled the DEJ of normal human skin (Figure
4a) and the dermal side of the salt-split human skin (Figure
4b). In contrast, serum from mice injected with control
normal human IgG did not bind to the DEJ of human skin
even at dilutions of 1:10 (Figure 4c).
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Figure 2. Clinical appearance of SKH1 mice injected with EBA antibodies.
(a–f) Middle back of SKH1 mice were injected intradermally with EBA
antibodies at 50 mg/g body weight once every day for 8 consecutive days. Four
to six days after the injections were started, animals developed numerous
blisters, erosions, and crusts forming from ruptured blisters (a, 4 and b,
6 ). Lesions were observed on the animals’ paws (d) at 10 days and neck
(c) at 6 weeks after the initial injections (8 ). Nail loss was also observed in
some mice (e and f). (g–i) Relation between the dose of EBA antibodies
injected into mice and the extent of cutaneous lesions induced in the animals.
The mice shown in panel g, panel h, and panel i received 50, 10, or 2.5 mg
IgG/g body weight, respectively, daily for 8 consecutive days. The arrows
point to areas of blisters and erosions induced by EBA antibodies 8 days after
the initial injections (8 ). No lesions were observed in the animal in panel i.
Table 2. Titers of affinity-purified EBA antibodies
correlates with the extent of disease in mice
Number of
mice
Dose of IgG
injected lg/g of
body weight/day
Extent of
disease1 IIF titer2
1 50 ++ 1,000
2 50 ++ 400
3 50 ++ 800
4 50 ++ 1,000
5 10 + 100
6 10 + 80
7 10 + 100
8 10 + 40
9 2.5  —
10 2.5  —
11 2.5  —
12 2.5  —
1Extent of disease was scored as follows: , no lesions; +, fewer than three
lesions; ++, more than three lesions and measured at 10 days after initial
injection.
2Titers of circulating IgG from injected mice tested against normal mouse
skin.
Disease activity and IIF titers were determined after mice were injected
with IgG dose as indicated above each day for 8 days.
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Immunogold electron microscopy examination of mice injected
with EBA antibodies
Direct immunogold electron microscopy of perilesional
mouse skin injected with EBA antibodies showed human
IgG deposits specifically localized to the lamina densa
(where anchoring fibrils insert), anchoring fibrils, and
anchoring plaques (Figure 5a). In lesional skin, a clear
dermal–epidermal separation was present in the sub-lamina
densa region (Figure 5b), similar to what is seen in human
EBA blisters. In contrast, mice that received control human
IgG injections had no deposits of human IgG at the DEJ of
mouse skin (data not shown).
F(ab0)2 fragments of pathogenic EBA autoantibodies do not
induce blisters
We wished to determine if complement activation was
required for the induction of blisters and nail loss in the
mice injected with human EBA autoantibodies. We prepared
F(ab0)2 fragments of the affinity-purified EBA autoantibodies
demonstrated to induce skin blisters by passive transfer
in mice. The complement binding, Fc domains, of the
antibodies were removed. We injected F(ab0)2 fragments into
SKH1 mice using equimolar doses as intact EBA IgG. In
contrast to the experiments with complete EBA IgG, the skin
of mice injected with F(ab0)2 did not develop clinical blisters
or any lesions (Figure 6a). When the skin of the injected mice
was subjected to DIF, the skin exhibited F(ab0)2 at the DEJ, but
no human IgG Fc or murine complement C3 (Figure 6b–d). As
expected, F(ab0)2 fragments prepared in an identical manner
from control human IgG and injected into the mice did not
induce lesions (data not shown).
DISCUSSION
In this study, we used human EBA patient sera to transfer
passively an EBA-like disease into hairless immunocompetent
mice. The human EBA sera were affinity-purified against the
NC1 domain of human type VII collagen producing high-titer
human anti-NC1 antibodies. When these anti-human NC1
antibodies were injected into the mice, the mice developed
sub-epidermal blisters, erosions, and nail loss, reminiscent of
the disease features seen in human EBA patients. By IIF
testing, we showed that the mice had anti-human NC1
antibodies circulating in their blood, again, similar to many
human EBA patients. By DIF on skin sites far away from the
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Figure 3. Histological and immunological examination of lesional skin of
SKH1 mice injected with EBA antibodies. (a and b) Histological appearance
of skin lesions induced by EBA autoantibodies. Hematoxylin and eosin
staining of (a) lesional murine skin revealed separation of the epidermis (E)
from the dermis (D). This histologic finding is similar to that seen in lesional
skin of EBA patients. (b) No epidermal–dermal separation was seen in mice
receiving equivalent amounts of normal human control IgG. (c) Immuno-
fluorescence analysis of SKH1 mice skin injected with EBA antibodies.
Cryosections of perilesional and lesional skin were labeled with FITC-
conjugated goat anti-human IgG (a-H IgG), FITC-conjugated goat anti-mouse
C3 (a-C3), and FITC-conjugated goat anti-mouse neutrophils (a-PMN),
respectively. Note the linear deposits of human IgG and murine C3 at the
BMZ of perilesional and lesional skin in mice injected with EBA antibodies.
Please also note the scattered neutrophils in the dermis. In contrast, in mice
receiving equivalent amounts of purified control normal human IgG (NHS),
no deposits of human IgG or murine C3 were detected. d, dermis;
e, epidermis. Original magnification,  25.
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Figure 4. Immunolabeling of human skin with serum from mice injected
with EBA antibodies. Sections of (a, c) normal human skin and (b) salt-split
human skin were stained with mouse serum obtained from mice injected with
either (a, b) EBA antibodies or (c) control human IgG at a dilution of 1:100.
Note that circulating antibodies labeling the BMZ of human skin and the
dermal floor of salt split human skin were found in the serum samples from
mice injected with EBA antibodies, but not in those injected with normal
human control IgG. d, dermis; e, epidermis.
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Figure 5. Immunoelectron microscopy of mice skin injected with EBA
antibodies. (a) Perilesional and (b) lesional skin of mice injected with affinity-
purified EBA autoantibodies were subjected to direct immunogold labeling
with goat anti-human IgG conjugated with a 1 nm gold particle. Note that the
injected human IgG specifically deposited along the lamina densa of the
BMZ, anchoring fibrils, and anchoring plaques. A split is also present in the
sub-lamina densa region of the lesional skin. Arrows denote gold particle-
labeled human IgG. D, dermis; E, epidermis; and HD, hemidesmosome.
Bars, for (a) 200 nm and for (b) 500 nm.
1326 Journal of Investigative Dermatology (2006), Volume 126
DT Woodley et al.
Passive Transfer of Autoantibodies from Patients
injected site on the back, such as the mouse’s ears, hips, or
paws, we detected human IgG deposits within the BMZ of the
mouse’s skin (data not shown). Likewise, we found human
IgG deposits at the junction of the esophageal epithelium and
lamina propria when we tested the upper one-third of the
animal’s esophagus by DIF. A few mice exhibited weight loss
after the eighth day injection period. We killed these mice
and noted erosions in their oral mucosa (data not shown).
Many, but not all, patients with EBA have involvement of the
oral mucosa and upper one-third of the esophagus. Like
human EBA patients, the injected anti-human NC1 antibodies
bound to the anchoring fibrils of the animals as demonstrated
by immunoelectron microscopy. Therefore, taken together,
the mice injected with human EBA patient autoantibodies
exhibited a blistering disease with clinical, histological, and
immunological features akin to human EBA patients.
The possibility that human EBA autoantibodies are patho-
genic has never before been proven, but was indirectly alluded
to by two recently described EBA mouse models published by
our group and another group (Sitaru et al., 2005; Woodley
et al., 2005). In these studies, rabbits were immunized with
type VII collagen and anti-type VII collagen rabbit IgG raised.
When injected into mice, these rabbit anti-type VII collagen
antibodies induced skin blisters suggestive of EBA (Sitaru et al.,
2005; Woodley et al., 2005). However, it is important to
recognize that these studies used immunized rabbit IgG rather
than human EBA patients’ sera. Therefore, these previous
studies with immunized rabbit antibodies did not prove
the pathogenicity of EBA patients’ autoantibodies. Several
previous attempts to demonstrate directly the pathogenicity of
human EBA autoantibodies by passively transferring them into
mice were unsuccessful (Shigemoto et al., 1988; Chen et al.,
1992; Borradori et al., 1995). There are several possible
reasons why previous attempts failed. First, Borradori et al.
(1995) used neonatal mice for IgG passive transfer and only
two injections were given. Therefore, the mice were exposed
to the antibody for a very limited incubation time. The
turnover of anchoring fibril structures is thought to be very
slow (Burgeson, 1993). Therefore, it is likely that the resident
anchoring fibrils in the mice may have continued to function
despite the presence of EBA autoantibodies. It is possible that
multiple injections of human EBA autoantibodies and a longer
period of time are needed to reproduce EBA in an animal. In
this study, we injected adult mice every day for 8 days.
Another potential problem encountered in previous studies
was that the amount of human anti-type VII collagen antibody
injected was too low. In our previous study, we did not inject
affinity-purified antibodies (Chen et al., 1992). Rather, we
injected the whole IgG fractions from EBA sera. The actual
amount of anti-type VII collagen antibody in these IgG
fractions was likely extremely low. In the study by Shigemoto
et al. (1988), EBA passive transfer was attempted in adult mice
for three consecutive days using total IgG. However, the
amount of total IgG fraction injected was only 0.13 mg/g body
weight. In this study, unlike previous attempts, we enriched
the actual anti-type VII collagen antibodies by affinity
purification against an NC1 domain affinity column and
concentrating the anti-NC1 antibody after the elution. There-
fore, virtually 100% of the antibodies injected into the animals
were specific for human type VII collagen. The titers of the
resultant affinity-purified antibodies were extremely high
(over 1:50,000 by IIF against human or mouse skin sections).
Type VII collagen is a large macromolecule with
approximately half of its molecular mass consumed by the
large, non-collagenous globular domain, NC1. We and
others have shown that NC1 domain of type VII collagen
contains four immunodominant epitopes targeted by the
majority of EBA sera (Gammon et al., 1993; Lapiere et al.,
1993; Jones et al., 1995). The fact that affinity-purified human
EBA sera against NC1 could produce the full-blown
manifestations of EBA in animals suggests that the main
pathogenic epitopes of type VII collagen reside within the
NC1 domain. Consistent with this notion is the fact that EBA
IgG antibodies depleted of any NC1 activity (i.e. the flow
through fractions from the NC1 affinity column) failed to
induce any lesions in the mice.
The etiology of EBA is unknown. Anchoring fibrils are
reduced in the skin of EBA patients, but the underlying
mechanism leading to this reduction is unknown (Nieboer
et al., 1980; Yaoita et al., 1981). One possible explanation for
diminished anchoring fibrils in EBA would be that the
antigen–antibody complex invokes an inflammatory response
that induces destruction of type VII collagen and other BMZ
components. This mechanism is perhaps predominant in the
inflammatory, BP-like, variety of EBA characterized by
vesiculobullous lesions on inflamed skin (Gammon et al.,
1982). Sitaru et al. (2005) showed that rabbit antibodies to the
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Figure 6. Clinical and immunological examination of SKH1 mice injected
with the F(ab0)2 fragments generated from EBA antibodies. (a) Clinical
appearance of skin injected with F(ab0)2 fragments at 40 mg/g body weight
once every day for 8 consecutive days showed no signs of skin blisters.
(b–d) Immunofluorescence analysis of SKH1 mice skin injected with F(ab0)2
fragments of EBA antibodies. Cryosections of injected skin were labeled with
FITC-conjugated (b) goat anti-human Fab, (c) goat anti-human Fc, and (d) goat
anti-mouse C3, respectively. Note the strong binding of F(ab0)2 fragments to
the BMZ, but the absence of Fc and murine C3 complement within the BMZ.
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NC1 domain of murine type VII collagen triggered an
inflammatory reaction with complement activation and the
recruitment of leukocytes. In this EBA murine model, blister
induction required the Fc portion of the rabbit IgG and
activation of terminal complement components (Sitaru et al.,
2005). Their data suggested that inflammation might be the
primary mechanism for blister formation in that model. In this
study, the administration of human EBA anti-type VII collagen
antibodies fixed murine complement at the DEJ. We further
demonstrated that injection of mice with pepsin-derived
F(ab0)2 fragments prepared from human EBA antibodies did
not induce clinical or histological EBA lesions. These data
suggest that the Fc domains of pathogenic EBA antibodies are
critical for sub-epidermal blister formation. As antibody-
specific activation of the complement system is mediated via
the Fc portion of IgG molecules, our results suggest that anti-
type VII collagen EBA antibodies induce sub-epidermal
blisters in our murine model via activation of the complement
system. In this regard, it is interesting to note that both of the
EBA patients used in this study had inflammatory EBA and C3
deposits at their DEJ by DIF.
However, because classical EBA presents with little skin
inflammation, another possible mechanism may be owing to
autoantibodies perturbing the ability of type VII collagen to
interact with other basement membrane components. That is,
the EBA autoantibodies target certain epitopes on the NC1
domain of type VII collagen and make the function of the
collagen compromised. This could perturb critical direct
interactions between type VII collagen and other extracellular
components within the DEJ such as type IV collagen, laminin-
5, and fibronectin (Lapiere et al., 1994; Chen et al., 1997a, b,
1999). This mechanism may explain the skin fragility and
trauma-induced blisters in patients with classical EBA who
lack significant inflammation but have markedly defective
epidermal–dermal adherence.
In summary, this study provides evidence that EBA
autoantibodies directed against type VII collagen are
pathogenic when passively transferred into hairless immuno-
competent mice. Our study establishes that EBA is an
example of a human autoimmune disorder that can be
passively transferred from human beings to laboratory
animals. This EBA experimental mouse model will be useful
for dissecting the molecular and immunological mechanisms
of sub-epidermal blister formation in EBA and for developing
more effective therapy for EBA.
MATERIALS AND METHODS
Patients and sera
Plasma samples were collected from two patients with EBA during
the early phase of their disease (before treatment). One patient was a
clear bullous-pemphigoid-like EBA patient with tense blisters on
inflammatory bases. Her initial IIF titer on salt-split skin was 1:320
but rose to 1:1,280 3 days before plasmaphoresis. The second
patient was a woman who was misdiagnosed as bullous pemphigoid
for at least 10 years, but then developed lesions on her hands, feet,
sacrum, and knees that more resembled classical EBA with skin
fragility, milia, and scarring in addition to more inflammatory
bullous-pemphigoid-like lesions on her trunk. Her IIF titers on
salt-split skin ranged between 1:1,280 and 1:5,120, with the latter
value 7 days before plasmaphoresis. These patients were plasma-
phoresed for therapeutic purposes, which generated large volumes
of plasma rich in anti-type VII collagen antibodies. In general, these
two EBA patients had (i) an active, chronic, bullous disease; (ii) sub-
epidermal blisters as assessed by routine light microscopy of lesional
skin; (iii) IgG and C3 deposits detected at the DEJ by routine DIF; (iv)
IgG deposits localized to the dermal floor of the patient’s skin when
the DEJ was fractured through the lamina lucida by treatment with
1 M NaCl (Woodley et al., 1983; Gammon et al., 1990); (v) immuno-
reactivity to the NC1 domain of type VII collagen by ELISA and
immunoblot analysis (Chen et al., 1997a, b); (vi) IgG deposits
detected within the sub-lamina densa region of the DEJ using direct
immunoelectron microscopy (Yaoita et al., 1981); and (vii) IIF on
salt-split normal human skin substrate demonstrating serum IgG
antibodies labeling the dermal floor of the substrate with the titers
ranging from 1:1,280 to 1:5,120. The study was conducted
according to the Declaration of Helsinki Principles and was
approved by the University of Southern California Institutional
Review Board. Patients gave their written informed consent.
Mice
SKH1 mice were obtained from Jackson Laboratories (Bar Harbor,
ME) and hosted at the University of Southern California Facility.
These are hairless mice with an intact immune system. Four- to
eight-week-old animals were injected with affinity-purified anti-type
VII collagen antibodies from the EBA patients’ sera or control IgG
fractions from the sera of normal human subjects at the same IgG
concentrations. All animal studies were conducted using protocols
approved by the University of Southern California Institutional
Animal Use Committee.
Preparation and characterization of IgG fractions
The patient’s plasma was first diluted with antibody binding buffer
(20 mM sodium phosphate, pH 7.0) at a 1:5 dilution and then
centrifuged at 4,000 r.p.m. to remove insoluble particulate material.
The supernatant were then subjected to chromatography using a
protein G-Sepharose Fast Flow column following the manufacturer’s
recommendation (Amersham Biosciences, Uppsala, Sweden). Con-
trol IgG fractions were prepared in an identical manner from a
commercial lot of human g-globulins obtained from several hundred
normal donors (Sigma, St Louis, MO). IgG fractions from EBA
patients were further affinity-purified using recombinant NC1
covalently coupled cyanogen bromide-activated Sepharose
4B column following the manufacturer’s instructions (Amersham
Bioscience, Sweden). The 145 kDa NC1 domain of human type
VII collagen was generated in human 293 cells by stable transfection
with a pRC/cytomegalovirus expression vector and purified
to homogeneity from conditioned media, as described previously
(Chen et al., 1997a, b). Affinity-purified EBA antibodies were
dialyzed against phosphate-buffered saline, concentrated
by Centricon Plus-20 ultrafiltration (Amicon, Lexinton, MA) to
20–50 mg/ml, filter-sterilized, and stored at 201C. By IIF, antibody
titers ranged from 1:10,000 to 1:50,000 on normal human skin,
mouse skin, and salt-split skin substrate. The affinity-purified
autoantibodies were also assessed by Western blot analyses and
ELISA as described (Gammon et al., 1984, 1990; Woodley, 1990;
Chen et al., 1997a, b).
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Preparation of F(ab0)2 fragments
F(ab0)2 fragments of affinity-purified EBA IgG autoantibodies were
prepared by digestion with pepsin as described (Liu et al., 1995).
Undigested IgG and Fc fragments were removed by affinity
chromatography using a protein G-Sepharose Fast Flow column
(Amersham Biosciences, Uppsala, Sweden). Purified F(ab0)2 frag-
ments migrated as a 100 kDa band under non-reduced SDS-PAGE.
The completeness of digestion was assessed by IIF using mouse skin
as substrate and F(ab0)2 preparations demonstrated reactivity only
with an FITC-labeled goat anti-human-F(ab0)2, but not with an FITC-
labeled goat anti-human-Fc secondary antibodies.
Administration of EBA antibodies, animal evaluation, and
characterization
SKHl mice were injected intradermally in the middle back of mice
with EBA IgG (n¼ 52), normal human control IgG (n¼ 10), or EBA
IgG-depleted NC1 reactivity (flow-through fractions from NC1
affinity column) (n¼ 5) once every day for 8 days and observed
every day. IgG doses ranged from 2.5 to 100 mg/g body weight/per
day. The animals were photographed daily. Skin erythema, blisters,
and erosions were recorded. Mice that developed blisters had skin
biopsies from the blisters and non-blistered normal-appearing skin
within 0.5 cm of a blister. Skin samples were fixed in 10% buffered
formalin and stained with hematoxylin and eosin. Both lesional and
perilesional tissues were subjected to DIF staining as previously
described (Gammon et al., 1990; Woodley et al., 1984). Mono-
specific FITC-conjugated sera were obtained commercially: goat
anti-human IgG (Sigma, St Louis, MO), monospecific goat anti-
mouse C3 (Cappel Laboratories, Durham, NC), goat anti-mouse
neutrophlis (Cedarlane, Ontario, Canada), goat anti-human F(ab0)2,
and Fc (Cappel Laboratories, Durham, NC). Photographs of
immunolabeled tissues were obtained with a Zeiss Axioplan
fluorescence microscope equipped with a Zeiss Axiocam MRM
digital camera system.
Direct immunogold electron microscopy was performed on the
lesional and perilesional regions of skin from SKH1 mice injected
with affinity-purified EBA antibodies. Following excision from the
mouse, these portions were incubated in goat anti-human 1-nm gold
conjugate (Amersham Biosciences, Piscataway, NJ) and further
processed for transmission electron microscopy as described
previously (Rousselle et al., 1991).
Sera were obtained from the mice at the time of the biopsy and
examined for anti-type VII collagen antibodies by IIF, Western blot
analysis, and ELISA, as described above (Gammon et al., 1984,
1990; Woodley, 1990; Chen et al., 1997a, b). Animals given normal
human control IgG or flow-through IgG fractions from NC1 affinity
column were studied in an identical fashion.
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